TRANSMAB:PD-L1 – a Novel Therapeutic Strategy Targeting Reactive Astrocytes & Glial Checkpoint in Alzheimer’s Disease

Time: 1:45 pm
day: Day Two


• Outlining the role of GFAP+ astrocytes in the neuroinflammatory cascade in neurodegeneration

• Exploring PD-L1+ GFAP+ astrocyte and PD-1+ microglia as a glial checkpoint and a potential novel therapeutic target against Alzheimer’s Disease

• Showcasing TRANSMAB:PD-L1 antibody ability to cross the BBB, reduce GFAP, and improve pathological outcome in preclinical AD models